Metformin is the key factor in elevated plasma growth differentiation factor‐15 levels in type 2 diabetes: A nested, case–control study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Produced as a tissue defence response to hypoxia and inflammation, growth differentiation factor‐15 (GDF‐15) is elevated in people receiving metformin treatment. To gain insight into the relationship of GDF‐15 with metformin and major cardiovascular risk factors, we analysed the data from the SUMMIT cohort (n = 1438), a four‐centre, nested, case–control study aimed at verifying whether biomarkers of atherosclerosis differ according to the presence of type 2 diabetes and cardiovascular disease. While in univariate analysis, major cardiovascular risk factors, with the exception of gender and cholesterol, increased similarly and linearly across GDF‐15 quartiles, the independent variables associated with GDF‐15, both in participants with and without diabetes, were age, plasma creatinine, N‐terminal pro‐brain natriuretic peptide, diuretic use, smoking exposure and glycated haemoglobin. In participants with diabetes, metformin treatment was associated with a 40% rise in GDF‐15 level, which was independent of the other major factors, and largely explained their elevated GDF‐15 levels. The relatively high GDF‐15 bioavailability might partly explain the protective cardiovascular effects of metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kempf, T., Eden, M., Strelau, J., Naguib, M., Willenbockel, C., Tongers, J., Heineke, J., Kotlarz, D., Xu, J., Molkentin, J. D., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000202805.73038.48 · Cited by 651
Adela, R., & Banerjee, S. K. (2015) · Journal of Diabetes Research · doi:10.1155/2015/490842 · Cited by 474 · cited 2×
“sclerosis, such as type 2 diabetes (T2D), impaired glucose tolerance and insulin resistance.(1,6) GDF-15 is also significantly upregulated in patients”
BackgroundSchlittenhardt, D., Schober, A., Strelau, J., Bonaterra, G. A., Schmiedt, W., Unsicker, K., Metz, J., & Kinscherf, R. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0986-3 · Cited by 224
Nesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211 · cited 1×
“Nevertheless, if metformin is able to upregulate GDF-15 circulating levels independently of other factors, this might represent a mechanism through which the drug exerts its effect in terms of CVD protection.(10) For this reason, we sought to identify the major determinants of plasma levels of GDF-15 separately in peo…”
BackgroundIdentifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia
Gerstein, H. C., Paré, G., McQueen, M. J., Haenel, H., Lee, S. F., Pogue, J., Maggioni, A. P., Yusuf, S., & Hess, S. (2015) · Circulation · doi:10.1161/circulationaha.115.015744 · Cited by 69
Cited by
Cellular and Molecular Mechanisms of Metformin Action
LaMoia, T. E., & Shulman, G. I. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa023 · Cited by 791
Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 699
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease
Wang, D., Day, E. A., Townsend, L. K., Djordjevic, D., Jørgensen, S. B., & Steinberg, G. R. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00529-7 · Cited by 516
Day, E. A., Ford, R. J., Smith, B. K., Mohammadi-Shemirani, P., Morrow, M. R., Gutgesell, R. M., Lu, R., Raphenya, A. R., Kabiri, M., McArthur, A. G., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0146-4 · Cited by 307
GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin
Ouyang, J., Isnard, S., Lin, J., Fombuena, B., Peng, X., Chen, Y., & Routy, J.-P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.581839 · Cited by 39
Metadata
- Authors
- Natali, A., Nesti, L., Venturi, E., Shore, A. C., Khan, F., Gooding, K., Gates, P. E., Looker, H. C., Dove, F., Goncalves, I., Persson, M., Nilsson, J., & on behalf of the SUMMIT consortium
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-10-02
- Volume
- 21
- Issue
- 2
- Pages
- 412-416
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2891296453
- Cited by
- 44
- References
- 5
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.